Circulating microRNA profile in patients with membranous obstruction of the inferior vena cava

Sun,Gui‑Xiang; Su,Yong; Li,Ying; Zhang,Ya‑Feng; Xu,Li‑Chun; Zu,Mao‑Heng; Huang,Shui‑Ping; Zhang,Jin‑Peng; Lu,Zhao‑Jun

doi:10.3892/etm.2016.2981

Circulating microRNA profile in patients with membranous obstruction of the inferior vena cava

Authors:
- Gui‑Xiang Sun
- Yong Su
- Ying Li
- Ya‑Feng Zhang
- Li‑Chun Xu
- Mao‑Heng Zu
- Shui‑Ping Huang
- Jin‑Peng Zhang
- Zhao‑Jun Lu
View Affiliations

Affiliations: Department of Public Health, Xuzhou Medical College, Xuzhou, Jiangsu 221004, P.R. China, Department of Interventional Radiology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221004, P.R. China
Published online on: January 12, 2016 https://doi.org/10.3892/etm.2016.2981
Pages: 811-817
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Membranous obstruction of the inferior vena cava (MOVC) is a common type of Budd-Chiari syndrome. However, the pathogenesis of MOVC has not been fully elucidated. Recent studies demonstrated that microRNAs (miRNAs or miRs) are involved in multiple diseases. To the best of our knowledge, specific changes in the expression of miRNAs in MOVC patients have not been previously assessed. The present study used a microarray analysis, followed by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) validation, with the aim to access the miRNA expression levels in the plasma of 34 MOVC patients, compared with those in healthy controls. The results revealed a total of 16 differentially expressed miRNAs in MOVC patients. Subsequently, RT‑qPCR analysis verified the statistically consistent expression of 5 selected miRNAs (miR‑125a‑5p, miR‑133b, miR‑423‑5p, miR‑1228‑5p and miR‑1266), in line with the results of the microarray analysis. These 5 miRNAs, which were described as crucial regulators in numerous biological processes and vascular diseases, may play an important role in the pathogenesis of MOVC. Bioinformatics analysis of target genes of the differentially expressed miRNAs revealed that these predicted targets were significantly enriched and involved in several key signaling pathways important for MOVC, including the ErbB, Wnt, MAPK and VEGF signaling pathway. In conclusion, miRNAs may involve in multiple signaling pathways contributing to the pathological processes of MOVC. The present study offers an intriguing new perspective on the involvement of miRNAs in MOVC; however, the precise underlying mechanisms require further validation.

View Figures

View References

1	Valla DC: Primary Budd-Chiari syndrome. J Hepatol. 50:195–203. 2009. View Article : Google Scholar : PubMed/NCBI
2	Hefaiedh R, Cheikh M, Marsaoui L, Ennaifer R, Romdhane H, Ben Nejma H, Bel Hadj N, Arfa N and Khalfallah MT: The Budd-Chiari syndrome. Tunis Med. 91:376–381. 2013.PubMed/NCBI
3	Leebeek FW, Smalberg JH and Janssen HL: Prothrombotic disorders in abdominal vein thrombosis. Neth J Med. 70:400–405. 2012.PubMed/NCBI
4	Plessier A, Rautou PE and Valla DC: Management of hepatic vascular diseases. J Hepatol. 56:S25–S38. 2012. View Article : Google Scholar : PubMed/NCBI
5	Plessier A and Valla DC: Budd-Chiari syndrome. Semin Liver Dis. 28:259–269. 2008. View Article : Google Scholar : PubMed/NCBI
6	Qi X, Han G, Wu F, Ren W, He C, Yin Z, Niu J, Bai M, Yang Z, Wu K and Fan D: Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature. Thromb Haemost. 109:878–884. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cheng D, Xu H, Lu ZJ, Hua R, Qiu H, Du H, Xu X and Zhang J: Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: A single. center study. J Gastroenterol Hepatol. 28:1061–1067. 2013. View Article : Google Scholar : PubMed/NCBI
8	Murad Darwish S, Plessier A, Hernandez-Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J, Morard I, Lasser L, Heller J, et al: EN-Vie (European Network for Vascular Disorders of the Liver): Etiology, management and outcome of the Budd-Chiari syndrome. Ann Intern Med. 151:167–175. 2009. View Article : Google Scholar : PubMed/NCBI
9	Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL and Leebeek FW: Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: A meta-analysis. Blood. 120:4921–4928. 2012. View Article : Google Scholar : PubMed/NCBI
10	Okuda K: Membranous obstruction of the inferior vena cava (obliterative hepatocavopathy, Okuda). J Gastroenterol Hepatol. 16:1179–1183. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wang ZG, Zhang FJ, Yi MQ and Qiang LX: Evolution of management for Budd-Chiari syndrome: A team's view from 2564 patients. ANZ J Surg. 75:55–63. 2005. View Article : Google Scholar : PubMed/NCBI
12	Qi X, Zhang C, Han G, Zhang W, He C, Yin Z, Liu Z, Bai W, Li R, Bai M, et al: Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: A prospective study. J Gastroenterol Hepatol. 27:1036–1043. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wang H, Sun G, Zhang P, Zhang J, Gui E, Zu M, Jia E, Xu H, Xu L, Zhang J and Lu Z: JAK2 V617F mutation and 46/1 haplotype in Chinese Budd-Chiari syndrome patients. J Gastroenterol Hepatol. 29:208–214. 2014. View Article : Google Scholar : PubMed/NCBI
14	Valla DC: Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol. 19:S204–S211. 2004. View Article : Google Scholar
15	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
17	Urbich C, Kuehbacher A and Dimmeler S: Role of microRNAs in vascular diseases, inflammation and angiogenesis. Cardiovasc Res. 79:581–588. 2008. View Article : Google Scholar : PubMed/NCBI
18	Small EM and Olson EN: Pervasive roles of microRNAs in cardiovascular biology. Nature. 469:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
19	Yue J, Guan J, Wang X, Zhang L, Yang Z, Ao Q, Deng Y, Zhu P and Wang G: MicroRNA-206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1α/Fhl-1 pathway. Lab Invest. 93:748–759. 2013. View Article : Google Scholar : PubMed/NCBI
20	Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, et al: MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. 113:1231–1241. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhao Z, Zhao Q, Warrick J, Lockwood CM, Woodworth A, Moley KH and Gronowski AM: Circulating microRNA miR-323-3p as a biomarker of ectopic pregnancy. Clin Chem. 58:896–905. 2012. View Article : Google Scholar : PubMed/NCBI
22	Tan L, Yu JT, Liu QY, Tan MS, Zhang W, Hu N, Wang YL, Sun L and Jiang T: Circulating miR-125b as a biomarker of Alzheimer's disease. J Neurol Sci. 336:52–56. 2014. View Article : Google Scholar : PubMed/NCBI
23	El-Hefnawy T, Raja S, Kelly L, Bigbee WL, Kirkwood JM, Luketich JD and Godfrey TE: Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem. 50:564–573. 2004. View Article : Google Scholar : PubMed/NCBI
24	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
25	Ach RA, Wang H and Curry B: Measuring microRNAs: Comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechno. 8:692008. View Article : Google Scholar
26	Kroh EM, Parkin RK, Mitchell PS and Tewari M: Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Li D, Yang P, Xiong Q, Song X, Yang X, Liu L, Yuan W and Rui YC: MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens. 28:1646–1654. 2010. View Article : Google Scholar : PubMed/NCBI
29	Wang E, Nie Y, Zhao Q, Wang W, Huang J, Liao Z, Zhang H, Hu S and Zheng Z: Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg. 8:1652013. View Article : Google Scholar : PubMed/NCBI
30	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
31	Chen L, Lu MH, Zhang D, Hao NB, Fan YH, Wu YY, Wang SM, Xie R, Fang DC, Zhang H, et al: miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. 5:e10342014. View Article : Google Scholar : PubMed/NCBI
32	Jia L, Wu J, Zhang L, Chen J, Zhong D, Xu S, Xie C and Cai J: Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer. PLoS One. 8:e586372013. View Article : Google Scholar : PubMed/NCBI
33	Fu Y, Yi Z, Wu X, Li J and Xu F: Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol. 49:4246–4251. 2011. View Article : Google Scholar : PubMed/NCBI
34	Li D, Yang P, Xiong Q, Song X, Yang X, Liu L, Yuan W and Rui YC: MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens. 28:1646–1654. 2010. View Article : Google Scholar : PubMed/NCBI
35	Reijerkerk A, Lopez-Ramirez MA, van Het Hof B, Drexhage JA, Kamphuis WW, Kooij G, Vos JB, van der Pouw Kraan TC, van Zonneveld AJ, Horrevoets AJ, et al: MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: Implications for multiple sclerosis. J Neurosci. 33:6857–6863. 2013. View Article : Google Scholar : PubMed/NCBI
36	Che P, Liu J, Shan Z, Wu R, Yao C, Cui J, Zhu X and Wang J, Burnett MS, Wang S and Wang J: MiR-125a-5p impairs endothelial cell angiogenesis in aging mice via RTEF-1 downregulation. Aging Cell. 13:926–934. 2014. View Article : Google Scholar : PubMed/NCBI
37	Hao L, Wang XG, Cheng JD, You SZ, Ma SH, Zhong X, Quan L and Luo B: The up-regulation of endothelin-1 and down-regulation of miRNA-125a-5p, −155 and −199a/b-3p in human atherosclerotic coronary artery. Cardiovasc Pathol. 23:217–223. 2014. View Article : Google Scholar : PubMed/NCBI
38	Dashwood MR and Tsui JC: Endothelin-1 and atherosclerosis: Potential complications associated with endothelin-receptor blockade. Atherosclerosis. 160:297–304. 2002. View Article : Google Scholar : PubMed/NCBI
39	Kowala MC: The role of endothelin in the pathogenesis of atherosclerosis. Adv Pharmacol. 37:299–318. 1997. View Article : Google Scholar : PubMed/NCBI
40	Zhao H, Li M, Li L, Yang X, Lan G and Zhang Y: MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
41	Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu B, Yan M, Yu Y, Liu B and Zhu Z: MiR-133b is frequently decreased in gastric cancer and its overexpression reduces the metastatic potential of gastric cancer cells. BMC Cancer. 14:342014. View Article : Google Scholar : PubMed/NCBI
42	Wang E, Nie Y, Zhao Q, Wang W, Huang J, Liao Z, Zhang H, Hu S and Zheng Z: Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg. 8:1652013. View Article : Google Scholar : PubMed/NCBI
43	Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE and Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res. 106:1035–1039. 2010. View Article : Google Scholar : PubMed/NCBI
44	Chen L, Lü MH, Zhang D, Hao NB, Fan YH, Wu YY, Wang SM, Xie R, Fang DC, Zhang H, et al: MiR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. 5:e10342014. View Article : Google Scholar : PubMed/NCBI
45	Jia L, Wu J, Zhang L, Chen J, Zhong D, Xu S, Xie C and Cai J: Restoration of miR-1228* expression suppresses epithelial-mesenchymal transition in gastric cancer. PLoS One. 8:e586372013. View Article : Google Scholar : PubMed/NCBI
46	Pentassuglia L and Sawyer DB: ErbB/integrin signaling interactions in regulation of myocardial cell-cell and cell-matrix interactions. Biochim Biophys Acta. 1833:909–916. 2013. View Article : Google Scholar : PubMed/NCBI
47	Koziński K and Dobrzyń A: Wnt signaling pathway-its role in regulation of cell metabolism. Postepy Hig Med Dosw (Online). 67:1098–1108. 2013. View Article : Google Scholar : PubMed/NCBI
48	Siddiqui SS, Siddiqui ZK, Uddin S, Minshall RD and Malik AB: P38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. Am J Physiol Lung Cell Mol Physiol. 292:L114–L124. 2007. View Article : Google Scholar : PubMed/NCBI
49	Liang X, Xu F, Li X, Ma C, Zhang Y and Xu W: VEGF signal system: The application of antiangiogenesis. Curr Med Chem. 21:894–910. 2014. View Article : Google Scholar : PubMed/NCBI
50	Shibuya M: Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 153:13–19. 2013. View Article : Google Scholar : PubMed/NCBI